Glucophage

Glucophage is a prescription medication that contains the active ingredient metformin hydrochloride, a biguanide oral antidiabetic agent. While specific strength and dosage form may vary, Glucophage is marketed in the European Union for the management of type 2 diabetes mellitus. It works by decreasing hepatic glucose production and improving peripheral insulin sensitivity, helping to control blood glucose levels in adults and is prescribed as part of a comprehensive diabetes care plan.

Glucophage is indicated for the treatment of type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

- Used as first‑line oral therapy for newly diagnosed patients. - Added to other antidiabetic agents when glycemic control is insufficient. - May be combined with insulin in patients requiring intensified therapy. - Utilized in patients with overweight or obesity to aid weight management. - Prescribed to improve insulin sensitivity in metabolic syndrome contexts (off‑label in some regions).

The safety profile of Glucophage includes a range of adverse effects that vary in frequency and severity. Most patients tolerate the medication, but monitoring is advised during therapy.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, and diarrhea. - Metallic taste in the mouth. - Decreased appetite leading to mild weight loss. - Vitamin B12 deficiency with long‑term use (monitoring recommended). - Flatulence and abdominal bloating.

Serious: - Lactic acidosis, a rare but potentially fatal metabolic complication. - Severe hypoglycemia when combined with insulin or sulfonylureas. - Hepatotoxicity manifested by elevated liver enzymes. - Acute pancreatitis, though rare, reported in some cases.

Before initiating Glucophage, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

- Assess renal function; contraindicated in severe renal impairment. - Review hepatic status; caution in liver disease. - Evaluate for conditions predisposing to hypoxia or heart failure. - Monitor for signs of lactic acidosis, especially after surgery or acute illness. - Check vitamin B12 levels periodically during long‑term therapy. - Use with caution in elderly patients due to increased risk of dehydration. - Avoid in pregnancy unless benefits outweigh risks (consult obstetric guidance).

Glucophage may interact with other medicines, affecting its efficacy or increasing the risk of adverse events.

Avoid: - Concomitant use with iodinated contrast agents due to heightened lactic acidosis risk. - Co‑administration with potent CYP2C8 inhibitors (e.g., gemfibrozil) that raise metformin plasma levels. - Combining with high‑dose alcohol or sedatives that may precipitate hypoglycemia.

Use with caution: - Concurrent insulin or sulfonylureas, which can increase hypoglycemia risk. - Diuretics and ACE inhibitors, requiring renal function monitoring. - Radiographic contrast procedures, necessitating temporary discontinuation of Glucophage. - Antiretroviral agents (e.g., protease inhibitors) that may alter metformin clearance.